Why Inventiva S.A.’s (IVA) Stock Is Down 7.46%
As of Wednesday, July 08, Inventiva S.A.’s IVA share price has dipped by 7.46%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Commentary & Analysis
Why Inventiva S.A.’s (IVA) Stock Is Up 6.10%
As of Thursday, July 02, Inventiva S.A.’s IVA share price has surged by 6.10%, which has investors questioning if this is right time to sell.Michael Rose
Why Inventiva S.A.’s (IVA) Stock Is Down 5.03%
As of Wednesday, July 01, Inventiva S.A.’s IVA share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Inventiva S.A.’s (IVA) Stock Is Up 5.21%
As of Tuesday, June 30, Inventiva S.A.’s IVA share price has surged by 5.21%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Inventiva S.A.’s (IVA) Stock Is Down 5.11%
As of Tuesday, June 16, Inventiva S.A.’s IVA share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | IVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,118.8 | $288.9 | 46% |
|
| Shares Out (Mil) | 310.9 | 54.0 | 83% |
|
| Institutional Ownership | 94.3% | 93.1% | 65% |
|
| Float (Mil) | 179.6 | 41.4 | 72% |
|
| Beta | 0.88 | 0.94 | 52% |
|
| Avg Daily Volume (000s) | 759 | 480 | 67% |
|
| Price Change (52-week) |
(7.6%) | 59.9% | 39% |
|
| Growth | IVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.3% | 14.1% | 33% |
|
| Net Income (5yr) | (58.9%) | (10.1%) | 5% |
|
| EPS (5yr) | (12.9%) | 15.9% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (65.5%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($416) | ($43) | 3% |
|
| EPS (TTM) | ($2.226) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($123) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $2 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $233 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $1,007 | $190 | 41% |
|
| Valuation | IVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 99.7% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (199.8%) | (47.7%) | 2% |
|
| ROE | 577.9% | (55.0%) | 100% |
|
| Liabilities to Assets | 111.4% | 29.6% | 96% |
|
| F-Score | 3 | 3 | 18% |
|
Inventiva S.A. did not pass any screens on 9/2/2026.
